含达雷妥尤单抗方案巩固和维持治疗高龄高危初治多发性骨髓瘤1例并文献复习

doi:10.3969/j.issn.1000-8535.2023.02.014

广州医药 ›› 2023, Vol. 54 ›› Issue (2): 70-74.DOI: 10.3969/j.issn.1000-8535.2023.02.014

含达雷妥尤单抗方案巩固和维持治疗高龄高危初治多发性骨髓瘤1例并文献复习

钟伟杰, 朱志刚

广州市第一人民医院老年病科血液肿瘤科(广州 510180)

收稿日期:2022-03-07 出版日期:2023-02-20 发布日期:2023-02-27
通讯作者: 钟伟杰,E-mail: eyweijiezhong@scut.edu.cn
基金资助:
广东省中医药局科研项目(20201252);广东省医学科学技术研究基金项目(A2020188);广州市科技计划项目(202002030175);华南理工大学中央高校基本科研业务费专项资金资助项目(D2200420)

Consolidation and maintenance therapy with daratumumab in elderly patient with high-risk newly diagnosed multiple myeloma: A case report and literature review

ZHONG Weijie, ZHU Zhigang

Department of Geriatrics, Hematology & Oncology Ward, Guangzhou First People's Hospital, Guangzhou 510180, China

Received:2022-03-07 Online:2023-02-20 Published:2023-02-27

摘要/Abstract

摘要： 目的观察达雷妥尤单抗联合来那度胺及地塞米松(DRd)方案巩固治疗序贯达雷妥尤单抗和来那度胺两药维持治疗1例高龄高危初治多发性骨髓瘤患者的疗效、生存时间和不良反应。方法回顾分析广州市第一人民医院老年病科血液肿瘤科2019年3月收治的1例高龄高危初治多发性骨髓瘤患者的临床资料,并复习相关最新文献。结果患者应用伊沙佐米、来那度胺和地塞米松方案诱导治疗13疗程后只达到部分缓解的疗效,未能进一步缓解,且不良反应多且严重,后改为DRd方案巩固治疗2疗程后,达到完全缓解,继续使用达雷妥尤单抗联合来那度胺两药维持治疗,不良反应少,至随访结束总生存期和无进展生存期均为35个月。结论含达雷妥尤单抗方案巩固和维持治疗可能会改善高龄高危初治多发性骨髓瘤患者的预后,延长生存时间,耐受性好。

关键词: 达雷妥尤单抗, 多发性骨髓瘤, 高龄, 高危

Abstract: Objective To observe the efficacy, survival time and adverse reactions of daratumumab combined with lenalidomide and dexamethasone (DRd) in the consolidation treatment of sequential daratumumab and lenalidomide maintenance treatment of an elderly patient with high-risk newly diagnosed multiple myeloma. Methods The clinical data of the elderly patient with newly diagnosed multiple myeloma treated in the Department of Geriatrics, Hematology & Oncology Ward, Guangzhou First People's Hospital in March 2019 were retrospectively analyzed, and the relevant latest literatures were reviewed. Results After 13 courses of induction treatment with isazomib, lenalidomide and dexamethasone, it only achieved partial remission, but failed to further remission, and there were many serious adverse reactions.Later, it was changed to DRd therapy to consolidate treatment.After 2 courses of treatment, it achieved complete remission.After that, we continued to use daratumumab combined with lenalidomide for maintenance treatment, with few adverse reactions.At the time of submission, the overall survival and progression free survival were 35 months. Conclusions Consolidation and maintenance therapy with daratumumab may improve the prognosis, prolong survival time and with good tolerance in elderly patients with high-risk newly diagnosed multiple myeloma.

Key words: daratumumab, multiple myeloma, elderly, high-risk

钟伟杰, 朱志刚. 含达雷妥尤单抗方案巩固和维持治疗高龄高危初治多发性骨髓瘤1例并文献复习[J]. 广州医药, 2023, 54(2): 70-74.

ZHONG Weijie, ZHU Zhigang. Consolidation and maintenance therapy with daratumumab in elderly patient with high-risk newly diagnosed multiple myeloma: A case report and literature review[J]. Guangzhou Medical Journal, 2023, 54(2): 70-74.

参考文献

[1] 万一柯,侯健.复发难治性多发性骨髓瘤治疗的现状与挑战.肿瘤防治研究[J],2019, 49(9):759-765.
[2] COWAN A, GREEN D, KWOK M, et al.Diagnosis and management of multiple myeloma: A review[J].JAMA,2022, 327(5):464-477.
[3] WALLINGTON-BEDDOE C, MYNOTT R.Prognostic and predictive biomarker developments in multiple myeloma[J].J Hematol Oncol,2021, 14(1):151.
[4] DERMAN B, KOSURI S, JAKUBOWIAK A.Knowing the unknowns in high risk multiple myeloma[J].Blood Revi,2022(51):100887.
[5] DU C, MAO X, XU Y, et al.1q21 gain but not t(4;14) indicates inferior outcomes in multiple myeloma treated with bortezomib[J].Leuk Lymphoma,2020, 61(5):1201-1210.
[6] 杨玉,林彩芹,李春雨,等.1q21扩增对于初治多发性骨髓瘤预后影响的异质性分析[J].临床血液学杂志,2021, 34(09):628-635.
[7] 中国医师协会血液科医师分会,中华医学会血液学分会,中国医师协会多发性骨髓瘤专业委员会.中国多发性骨髓瘤诊治指南(2020年修订)[J].中华内科杂志,2020, 59(5):341-346.
[8] KUMAR S K, BERDEJA J G, NIESVIZKY R, et al.Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study[J].Lancet Oncol,2014, 15(13):1503-1512.
[9] de WEERS M, TAI Y T, van DER VEER M S, et al.Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors[J].J Immunol,2011, 186(3):1840-1848.
[10] LOKHORST H M, PLESNER T, LAUBACH J P, et al.Targeting CD38 with daratumumab monotherapy in multiple myeloma[J].N Engl J Med,2015, 373(13):1207-1219.
[11] NIJHOF I S, GROEN R W, NOORT W A, et al.Preclinical evidence for the therapeutic potential of CD38-targeted immuno-chemotherapy in multiple myeloma patients refractory to lenalidomide and bortezomib[J].Clin Cancer Res,2015, 21(12):2802-2810.
[12] VIOLA D, DONA A, CASERTA E, et al.Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting[J].Leukemia,2021, 35(1):189-200.
[13] USMANI S Z, WEISS B M, PLESNER T, et al.Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma[J].Blood,2016, 128(1):37-44.
[14] BAHLIS N J, DIMOPOULOS M A, WHITE D J, et al.Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study[J].Leukemia,2020, 34(7):1875-1884.
[15] SUZUKI K, DIMOPOULOS M A, TAKEZAKO N, et al.Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study[J].Blood Cancer J,2018, 8(4):41.
[16] FACON T, KUMAR S, PLESNER T, et al.Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial[J].The Lancet Oncology, 2021, 22(11):1582-1596.
[17] MATEOS M, CAVO M, BLADE J, et al.Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial[J].Lancet (London, England),2020, 395(10218):132-141.
[18] MOHYUDDIN G R, MIAN H.Daratumumab in newly diagnosed MM-incorporating lessons learnt from CASSIOPEIA, MAIA and beyond[J].Nat Rev Clin Oncol,2022, 19(1):3-4.

含达雷妥尤单抗方案巩固和维持治疗高龄高危初治多发性骨髓瘤1例并文献复习

Consolidation and maintenance therapy with daratumumab in elderly patient with high-risk newly diagnosed multiple myeloma: A case report and literature review

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	黄文冲, 汤间仪, 马慧. 数字乳腺三维断层融合摄影技术联合MR波谱在乳腺高危病灶诊断中的应用[J]. 广州医药, 2023, 54(1): 52-55.
[2]	黄千峰, 何琴, 何裕, 邓娟琼, 林杏芳, 张秀. 广东粤西北农村妇女高危型HPV感染情况分析[J]. 广州医药, 2022, 53(6): 22-26.
[3]	李诗函, 马煜磊. 阴道灌洗液中炎性因子表达水平与高危型HPV持续感染的相关性[J]. 广州医药, 2022, 53(3): 46-48.
[4]	叶志华, 余家康, 王哲, 何秋明, 钟微. Ⅲ型食管闭锁术后气管食管瘘复发的高危因素[J]. 广州医药, 2022, 53(1): 81-86.
[5]	郑素娟, 冯彩莲, 樊建凤. 高龄呼吸道感染患者病原菌检验以及耐药性监测结果分析[J]. 广州医药, 2021, 52(6): 83-86.
[6]	邓雨果, 黄子健. 核苷类似物治疗宫颈人乳头瘤病毒感染的疗效[J]. 广州医药, 2021, 52(2): 11-16.
[7]	黄文宇, 林永汉, 熊小英. 孕中后期中低等强度有氧运动对高龄孕妇产前生活质量和母婴结局的影响探讨[J]. 广州医药, 2020, 51(5): 66-70.
[8]	王宁, 杜新, 张晓瀚, 李思达, 朱锦灿, 徐舒. PAD方案治疗初发多发性骨髓瘤的疗效及安全性[J]. 广州医药, 2020, 51(4): 13-17.
[9]	黄月娥, 李志根, 李丹莉, 蒋妍琳. 高龄患者植入静脉输液港并发感染相关影响因素分析[J]. 广州医药, 2020, 51(4): 71-74.
[10]	陈佳, 林颖仪, 高薇薇, 叶秀桢. 广东地区新生儿肠道病毒感染的高危因素分析[J]. 广州医药, 2020, 51(2): 123-126.
[11]	王强, 邓树酬, 钟俊斌, 陈转鹏, 钟秉政, 魏建昌, 曹杰. 高龄患者腹股沟嵌顿疝术后肺部感染的相关因素分析[J]. 广州医药, 2019, 50(1): 44-48.
[12]	黄小权, 王琴, 洪少琼. 早期康复训练对高龄股骨骨折内固定患者术后康复的影响[J]. 广州医药, 2019, 50(1): 118-120.
[13]	刘力, 刘世乐, 刘晓磊. 腹横肌平面阻滞在高危产妇剖宫产手术中的应用[J]. 广州医药, 2018, 49(6): 88-90.
[14]	粟琼瑜, 刘洁珍, 蔡琼, 邝玉群. 个体化健康管理对超高龄结直肠癌患者希望水平的影响[J]. 广州医药, 2017, 48(3): 75-77.
[15]	郑彬, 郭静文, 唐晶晶, 罗兵, 阮祥才, 许立新, 佘守章. 围术期目标导向液体治疗用于老年高危患者的研究[J]. 广州医药, 2016, 47(2): 17-20.